Citation: | HE Wei, QI Haixia, DONG Lei, ZHANG Junfeng. Research advances in drug delivery system targeting immune system[J]. Journal of China Pharmaceutical University, 2015, 46(5): 513-520. DOI: 10.11665/j.issn.1000-5048.20150501 |
[1] |
Lopalco G,Cantarini L,Vitale A,et al.Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders:premises,perils,and perspectives[J].Mediators Inflamm,2015,2015:194864.
|
[2] |
Monti P,Bonifacio E.Interleukin-7 and type 1 diabetes[J].Curr Diab Rep,2014,14(9):518.
|
[3] |
Singh A,Talekar M,Raikar A,et al.Macrophage-targeted delivery systems for nucleic acid therapy of inflammatory diseases[J].J Control Release,2014,190:515-530.
|
[4] |
Murray PJ,Wynn TA.Protective and pathogenic functions of macrophage subsets[J].Nat Rev Immunol,2011,11(11):723-737.
|
[5] |
Mosser DM,Edwards JP.Exploring the full spectrum of macrophage activation[J].Nat Rev Immunol,2008,8(12):958-969.
|
[6] |
Ruffell B,Affara NI,Coussens LM.Differential macrophage programming in the tumor microenvironment[J].Trends Immunol,2012,33(3):119-126.
|
[7] |
Nakashima-Matsushita N, Homma T, Yu S, et al. Selective expression of folate receptor beta and its possible role in methotrexate transport in synovial macrophages from patients with rheumatoid arthritis[J].Arthritis Rheum,1999,42(8):1609-1616.
|
[8] |
Bilthariya U,Jain N,Rajoriya V,et al.Folate-conjugated albumin nanoparticles for rheumatoid arthritis-targeted delivery of etoricoxib[J].Drug Dev Ind Pharm,2015,41(1):95-104.
|
[9] |
Thomas TP,Goonewardena SN,Majoros IJ,et al.Folate-targeted nanoparticles show efficacy in the treatment of inflammatory arthritis[J].Arthritis Rheum,2011,63(9):2671-2680.
|
[10] |
Ayala-Lopez W,Xia W,Varghese B,et al.Imaging of atherosclerosis in apoliprotein e knockout mice:targeting of a folate-conjugated radiopharmaceutical to activated macrophages[J].J Nucl Med,2010,51(5):768-774.
|
[11] |
Furusho Y,Miyata M,Matsuyama T,et al.Novel therapy for atherosclerosis using recombinant immunotoxin against folate receptor beta-expressing macrophages[J].J Am Heart Assoc,2012,1(4):e3079.
|
[12] |
Taylor PR, Martinez-Pomares L, Stacey M, et al. Macrophage receptors and immune recognition[J].Annu Rev Immunol,2005,23:901-944.
|
[13] |
Stahl P,Schlesinger PH,Sigardson E,et al.Receptor-mediated pinocytosis of mannose glycoconjugates by macrophages:characterization and evidence for receptor recycling[J].Cell,1980,19(1):207-215.
|
[14] |
Kriegel C,Amiji M.Oral TNF-alpha gene silencing using a polymeric microsphere-based delivery system for the treatment of inflammatory bowel disease[J].J Control Release,2011,150(1):77-86.
|
[15] |
Xiao B,Laroui H,Ayyadurai S,et al.Mannosylated bioreducible nanoparticle-mediated macrophage-specific TNF-alpha RNA interference for IBD therapy[J].Biomaterials,2013,34(30):7471-7482.
|
[16] |
Asthana GS,Asthana A,Kohli DV,et al.Mannosylated chitosan nanoparticles for delivery of antisense oligonucleotides for macrophage targeting[J].Biomed Res Int,2014,2014:526391.
|
[17] |
Huang Z,Gan J,Jia L,et al.An orally administrated nucleotide-delivery vehicle targeting colonic macrophages for the treatment of inflammatory bowel disease[J].Biomaterials,2015,48:26-36.
|
[18] |
Solinas G,Germano G,Mantovani A,et al.Tumor-associated macrophages(TAM)as major players of the cancer-related inflammation[J].J Leukocyte Biol,2009,86(5):1065-1073.
|
[19] |
Amoozgar Z,Goldberg MS.Targeting myeloid cells using nanoparticles to improve cancer immunotherapy[J].Adv Drug Deliv Rev,2014,doi: 10.1016/j.addr.2014.09.007.
|
[20] |
Zhan X,Jia L,Niu Y,et al.Targeted depletion of tumour-associated macrophages by an alendronate-glucomannan conjugate for cancer immunotherapy[J].Biomaterials,2014,35(38):10046-10057.
|
[21] |
Huang Z,Yang Y,Jiang Y,et al.Anti-tumor immune responses of tumor-associated macrophages via toll-like receptor 4 triggered by cationic polymers[J].Biomaterials,2013,34(3):746-755.
|
[22] |
Kono Y,Kawakami S,Higuchi Y,et al.Antitumor effect of nuclear factor-kappaB decoy transfer by mannose-modified bubble lipoplex into macrophages in mouse malignant ascites[J].Cancer Sci,2014,105(8):1049-1055.
|
[23] |
Locke LW,Mayo MW,Yoo AD,et al.PET imaging of tumor associated macrophages using mannose coated 64Cu liposomes[J].Biomaterials,2012,33(31):7785-7793.
|
[24] |
Zuo L,Huang Z,Dong L,et al.Targeting delivery of anti-TNF alpha oligonucleotide into activated colonic macrophages protects against experimental colitis[J].Gut,2010,59(4):470-479.
|
[25] |
Dong L,Gao S,Diao H,et al.Galactosylated low molecular weight chitosan as a carrier delivering oligonucleotides to Kupffer cells instead of hepatocytes in vivo[J].J Biomed Mater Res A,2008,84(3):777-784.
|
[26] |
Huang Z,Zhang Z,Jiang Y,et al.Targeted delivery of oligonucleotides into tumor-associated macrophages for cancer immunothe-rapy[J].J Control Release,2012,158(2):286-292.
|
[27] |
Jain S,Amiji M.Tuftsin-modified alginate nanoparticles as a noncondensing macrophage-targeted DNA delivery system[J].Biomacromolecules,2012,13(4):1074-1085.
|
[28] |
Jain S,Amiji M.Tuftsin-modified alginate nanoparticles as a noncondensing macrophage-targeted DNA delivery system[J].Biomacromolecules,2012,13(4):1074-1085.
|
[29] |
Laroui H,Geem D,Xiao B,et al.Targeting intestinal inflammation with CD98 siRNA/PEI-loaded nanoparticles[J].Mol Ther,2014,22(1):69-80.
|
[30] |
Kriegel C,Amiji MM.Dual TNF-alpha/Cyclin D1 gene silencing with an oral polymeric microparticle system as a novel strategy for the treatment of inflammatory bowel disease[J].Clin Transl Gastroenterol,2011,2:e2.
|
[31] |
Khan S,Greenberg JD,Bhardwaj N.Dendritic cells as targets for therapy in rheumatoid arthritis[J].Nat Rev Rheumatol,2009,5(10):566-571.
|
[32] |
Zhou L,Chong MM,Littman DR.Plasticity of CD4+ T cell lineage differentiation[J].Immunity,2009,30(5):646-655.
|
[33] |
Ohnmacht C,Pullner A,King SB,et al.Constitutive ablation of dendritic cells breaks self-tolerance of CD4 T cells and results in spontaneous fatal autoimmunity[J].J Exp Med,2009,206(3):549-559.
|
[34] |
Hamdy S,Haddadi A,Hung RW,et al.Targeting dendritic cells with nano-particulate PLGA cancer vaccine formulations[J].Adv Drug Deliv Rev,2011,63(10/11):943-955.
|
[35] |
Pichon C,Midoux P.Mannosylated and histidylated LPR technology for vaccination with tumor antigen mRNA[J].Methods Mol Biol,2013,969:247-274.
|
[36] |
Li P,Chen S,Jiang Y,et al.Dendritic cell targeted liposomes-protamine-DNA complexes mediated by synthetic mannosylated cholesterol as a potential carrier for DNA vaccine[J].Nanotechnology,2013,24(29):295101.
|
[37] |
Rosalia RA,Cruz LJ,van Duikeren S,et al.CD40-targeted dendritic cell delivery of PLGA-nanoparticle vaccines induce potent anti-tumor responses[J].Biomaterials,2015,40:88-97.
|
[38] |
Ejaz A,Ammann CG,Werner R,et al.Targeting viral antigens to CD11c on dendritic cells induces retrovirus-specific T cell responses[J].PLoS One,2012,7(9):e45102.
|
[39] |
Ahonen CL,Doxsee CL,McGurran SM,et al.Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN[J].J Exp Med,2004,199(6):775-784.
|
[40] |
Manolova V,Flace A,Bauer M,et al.Nanoparticles target distinct dendritic cell populations according to their size[J].Eur J Immunol,2008,38(5):1404-1413.
|
[41] |
Ruff LE,Mahmoud EA,Sankaranarayanan J,et al.Antigen-loaded pH-sensitive hydrogel microparticles are taken up by dendritic cells with no requirement for targeting antibodies[J].Integr Biol(Camb),2013,5(1):195-203.
|
[42] |
Baleeiro RB,Wiesmuller KH,Reiter Y,et al.Topical vaccination with functionalized particles targeting dendritic cells[J].J Invest Dermatol,2013,133(8):1933-1941.
|
[43] |
Saluja SS,Hanlon DJ,Sharp FA,et al.Targeting human dendritic cells via DEC-205 using PLGA nanoparticles leads to enhanced cross-presentation of a melanoma-associated antigen[J].Int J Nanomedicine,2014,9:5231-5246.
|
[44] |
Cruz LJ,Rueda F,Simon L,et al.Liposomes containing NYESO1/tetanus toxoid and adjuvant peptides targeted to human dendritic cells via the Fc receptor for cancer vaccines[J].Nanomedicine(Lond),2014,9(4):435-449.
|
[45] |
Hamdy S,Molavi O,Ma Z,et al.Co-delivery of cancer-associated antigen and Toll-like receptor 4 ligand in PLGA nanoparticles induces potent CD8+ T cell-mediated anti-tumor immunity[J].Vaccine,2008,26(39):5046-5057.
|
[46] |
Nikitczuk KP, Schloss RS, Yarmush ML, et al. PLGA-polymer encapsulating tumor antigen and CpG DNA administered into the tumor microenvironment elicits a systemic antigen-specific IFN-gamma response and enhances survival[J].J Cancer Ther,2013,4(1):280-290.
|
[47] |
Mueller M,Reichardt W,Koerner J,et al.Coencapsulation of tumor lysate and CpG-ODN in PLGA-microspheres enables successful immunotherapy of prostate carcinoma in TRAMP mice[J].J Control Release,2012,162(1):159-166.
|
[48] |
Heit A,Schmitz F,Haas T,et al.Antigen co-encapsulated with adjuvants efficiently drive protective T cell immunity[J].Eur J Immunol,2007,37(8):2063-2074.
|
[49] |
Palumbo RN,Nagarajan L,Wang C.Recombinant monomeric CD40 ligand for delivering polymer particles to dendritic cells[J].Biotechnol Prog,2011,27(3):830-837.
|
[50] |
Bourquin C,Anz D,Zwiorek K,et al.Targeting CpG oligonucleotides to the lymph node by nanoparticles elicits efficient antitumoral immunity[J].J Immunol,2008,181(5):2990-2998.
|
[51] |
Machy P,Serre K,Leserman L.Class I-restricted presentation of exogenous antigen acquired by Fcγ receptor-mediated endocytosis is regulated in dendritic cells[J].Eur J Immunol,2000,30(3):848-857.
|
[52] |
Prasad S,Cody V,Saucier-Sawyer JK,et al.Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy[J].Nanomedicine,2011,7(1):1-10.
|
[53] |
Solbrig CM,Saucier-Sawyer JK,Cody V,et al.Polymer nanoparticles for immunotherapy from encapsulated tumor-associated antigens and whole tumor cells[J].Mol Pharm,2007,4(1):47-57.
|
[54] |
Prasad S,Cody V,Saucier-Sawyer JK,et al.Polymer nanoparticles containing tumor lysates as antigen delivery vehicles for dendritic cell-based antitumor immunotherapy[J].Nanomedicine,2011,7(1):1-10.
|
[55] |
Pateinakis P,Pyrpasopoulou A.Targeting the B-cell pathway in lupus nephritis:current evidence and future perspectives[J].Scientific World Journal,2013,2013:745239.
|
[56] |
Ding Q,Chen J,Wei X,et al.RAFTsomes containing epitope-MHC-II complexes mediated CD4+ T cell activation and antigen-specific immune responses[J].Pharm Res,2013,30(1):60-69.
|
[57] |
Boot EP,Koning GA,Storm G,et al.CD134 as target for specific drug delivery to auto-aggressive CD4+ T cells in adjuvant arthritis[J].Arthritis Res Ther,2005,7(3):R604-R615.
|
[58] |
Mezzaroba N,Zorzet S,Secco E,et al.New potential therapeutic approach for the treatment of B-Cell malignancies using chlorambucil/hydroxychloroquine-loaded anti-CD20 nanoparticles[J].PLoS One,2013,8(9):e74216.
|
[59] |
Mao Y,Triantafillou G,Hertlein E,et al.Milatuzumab-conjugated liposomes as targeted dexamethasone carriers for therapeutic delivery in CD74+ B-cell malignancies[J].Clin Cancer Res,2013,19(2):347-356.
|
[60] |
Chen WC,Completo GC,Sigal DS,et al.In vivo targeting of B-cell lymphoma with glycan ligands of CD22[J].Blood,2010,115(23):4778-4786.
|
[61] |
Cheng WW,Allen TM.Targeted delivery of anti-CD19 liposomal doxorubicin in B-cell lymphoma:a comparison of whole monoclonal antibody,Fab′ fragments and single chain Fv[J].J Control Release,2008,126(1):50-58.
|
[62] |
Zhang XY,Lu WY.Recent advances in lymphatic targeted drug delivery system for tumor metastasis[J].Cancer Biol Med,2014,11(4):247-254.
|
[63] |
Flanagan J,Singh H.Microemulsions:a potential delivery system for bioactives in food[J].Crit Rev Food Sci Nutr,2006,46(3):221-237.
|
[64] |
He XW,Liu T,Chen YX,et al.Calcium carbonate nanoparticle delivering vascular endothelial growth factor-C siRNA effectively inhibits lymphangiogenesis and growth of gastric cancer in vivo[J].Cancer Gene Ther,2008,15(3):193-202.
|
[65] |
Yan Z,Zhan C,Wen Z,et al.LyP-1-conjugated doxorubicin-loaded liposomes suppress lymphatic metastasis by inhibiting lymph node metastases and destroying tumor lymphatics[J].Nanotechnology,2011,22(41):415103.
|
[66] |
Feng L,Zhang L,Liu M,et al.Roles of dextrans on improving lymphatic drainage for liposomal drug delivery system[J].J Drug Target,2010,18(3):168-178.
|
[67] |
Tiantian Y,Wenji Z,Mingshuang S,et al.Study on intralymphatic-targeted hyaluronic acid-modified nanoliposome:influence of formulation factors on the lymphatic targeting[J].Int J Pharm,2014,471(1/2):245-257.
|
[68] |
Cobaleda-Siles M,Henriksen-Lacey M,Ruiz DAA,et al.An iron oxide nanocarrier for dsRNA to target lymph nodes and strongly activate cells of the immune system[J].Small,2014,10(24):5054-5067.
|
[69] |
Aji AM,Chacko AJ,Jose S,et al.Lopinavir loaded solid lipid nanoparticles(SLN)for intestinal lymphatic targeting[J].Eur J Pharm Sci,2011,42(1/2):11-18.
|
[70] |
Huang Z,Zhang Z,Zha Y,et al.The effect of targeted delivery of anti-TNF-alpha oligonucleotide into CD169+ macrophages on disease progression in lupus-prone MRL/lpr mice[J].Biomaterials,2012,33(30):7605-7612.
|